Core Viewpoint - Future Health, the parent company of the SKG massage device brand, has submitted an application for a mainboard listing on the Hong Kong Stock Exchange after a tumultuous IPO journey in China [1][15]. Financial Performance - Future Health reported total revenues of 9.05 billion yuan, 10.46 billion yuan, and 10.45 billion yuan for the years 2022, 2023, and 2024 respectively, with adjusted net profits of 1.37 billion yuan, 1.23 billion yuan, and 1.26 billion yuan, maintaining a gross margin around 50% [1][15]. - For the first three quarters of 2025, the company achieved approximately 8.78 billion yuan in total revenue, a year-on-year increase of 16.2%, and an adjusted net profit of about 1.18 billion yuan, a significant increase of 58.8% compared to the same period in 2024 [2][16]. Product Performance - The sales of the core product, the SKG neck massage device, have stagnated, with sales volume fluctuating and showing a slight increase of 3.2% in the first three quarters of 2025, but revenue from this product category decreased by 1.8% [3][20]. - Other products, such as the eye and waist massage devices, have not developed as expected, with sales declining by 16.8% and 0.8% respectively in the first nine months of 2025 [5][20]. Marketing and R&D - Future Health has heavily invested in marketing, with sales and marketing expenses rising from 1.64 billion yuan in 2022 to 1.98 billion yuan in 2025, while R&D expenses have decreased, leading to a lower R&D expense ratio from 9.1% to 6.6% [7][22]. - The company has relied on celebrity endorsements for marketing, with significant spending on endorsements, which accounted for about 10% of sales and marketing expenses in 2021-2022 [6][21]. Customer Concentration and Financial Health - Future Health's revenue is highly concentrated, with the top five customers contributing over 40% of total revenue, which poses risks to the company's financial stability [11][24]. - The company has been generous with cash dividends, distributing a total of 5.94 billion yuan from 2020 to 2023, while also increasing its bank borrowings by 176.8% to 1.80 billion yuan as of September 30, 2025, raising concerns about its financial management [12][28].

Core Viewpoint - Future Health, the parent company of SKG, has officially terminated its IPO plans on the Beijing Stock Exchange due to strategic development needs, following a series of unsuccessful attempts to go public [2][5][6]. Group 1: Company Overview - Future Health, established in 2007, focuses on smart wearable health products, with its main brand SKG specializing in products like neck and eye massagers, muscle guns, and health watches [3]. - As of September 2023, over 80% of Future Health's revenue comes from wearable health products, with neck and waist massagers being the most significant product lines [3]. Group 2: Financial Performance - Future Health reported revenues of 1.048 billion CNY in the latest period, a slight increase of 0.2% from the previous year, with a net profit of approximately 135.46 million CNY, reflecting a 7% increase [4]. - The company has seen fluctuating revenues over the years, with reported revenues of 10.54 billion CNY in 2021, 9.04 billion CNY in 2022, and around 10.48 billion CNY in 2024 [3]. Group 3: IPO Journey - Future Health's IPO journey has been tumultuous, having previously attempted to list on the ChiNext board before shifting focus to the Beijing Stock Exchange [5][7]. - The company faced multiple setbacks, including two suspensions of its IPO review due to outdated financial documents and a withdrawal of its application after significant scrutiny from regulators regarding its dividend policies and executive compensation [6]. Group 4: Strategic Focus and Marketing - In recent years, Future Health has prioritized international expansion, with SKG accelerating its overseas efforts and signing a strategic investment agreement with Morgan Stanley [8]. - The company has invested heavily in marketing, with sales expenses reaching 118 million CNY in the first half of 2024, accounting for 19.8% of its revenue, although overseas revenue saw a decline of 14.18% during the same period [13].